» Articles » PMID: 23567086

Decoding Cell Death Signals in Liver Inflammation

Overview
Journal J Hepatol
Publisher Elsevier
Specialty Gastroenterology
Date 2013 Apr 10
PMID 23567086
Citations 436
Authors
Affiliations
Soon will be listed here.
Abstract

Inflammation can be either beneficial or detrimental to the liver, depending on multiple factors. Mild (i.e., limited in intensity and destined to resolve) inflammatory responses have indeed been shown to exert consistent hepatoprotective effects, contributing to tissue repair and promoting the re-establishment of homeostasis. Conversely, excessive (i.e., disproportionate in intensity and permanent) inflammation may induce a massive loss of hepatocytes and hence exacerbate the severity of various hepatic conditions, including ischemia-reperfusion injury, systemic metabolic alterations (e.g., obesity, diabetes, non-alcoholic fatty liver disorders), alcoholic hepatitis, intoxication by xenobiotics and infection, de facto being associated with irreversible liver damage, fibrosis, and carcinogenesis. Both liver-resident cells (e.g., Kupffer cells, hepatic stellate cells, sinusoidal endothelial cells) and cells that are recruited in response to injury (e.g., monocytes, macrophages, dendritic cells, natural killer cells) emit pro-inflammatory signals including - but not limited to - cytokines, chemokines, lipid messengers, and reactive oxygen species that contribute to the apoptotic or necrotic demise of hepatocytes. In turn, dying hepatocytes release damage-associated molecular patterns that-upon binding to evolutionary conserved pattern recognition receptors-activate cells of the innate immune system to further stimulate inflammatory responses, hence establishing a highly hepatotoxic feedforward cycle of inflammation and cell death. In this review, we discuss the cellular and molecular mechanisms that account for the most deleterious effect of hepatic inflammation at the cellular level, that is, the initiation of a massive cell death response among hepatocytes.

Citing Articles

The Malignant Transformation of Viral Hepatitis to Hepatocellular Carcinoma: Mechanisms and Interventions.

Yuan H, Xu R, Li S, Zheng M, Tong Q, Xiang M MedComm (2020). 2025; 6(3):e70121.

PMID: 40060195 PMC: 11890166. DOI: 10.1002/mco2.70121.


Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis.

Devasia A, Ramasamy A, Leo C Int J Mol Sci. 2025; 26(4).

PMID: 40004240 PMC: 11855529. DOI: 10.3390/ijms26041778.


Examination of the causal role of immune cells in non-alcoholic fatty liver disease by a bidirectional Mendelian randomization study.

Li Y, Lv X, Lin J, Li S, Lin G, Huang Z Open Med (Wars). 2025; 20(1):20251154.

PMID: 39989616 PMC: 11843165. DOI: 10.1515/med-2025-1154.


Protective role of ginsenoside Rg1 in the dynamic progression of liver injury to fibrosis: a preclinical meta-analysis.

Dan L, Li X, Chen S, You X, Wang D, Wang T Front Pharmacol. 2025; 16:1512184.

PMID: 39936090 PMC: 11810943. DOI: 10.3389/fphar.2025.1512184.


Advances, challenges and future applications of liver organoids in experimental regenerative medicine.

Gong D, Mo J, Zhai M, Zhou F, Wang G, Ma S Front Med (Lausanne). 2025; 11:1521851.

PMID: 39927267 PMC: 11804114. DOI: 10.3389/fmed.2024.1521851.